⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 8, 2025

Figure S4 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Zahra Davoudi Thomas S. Dexheimer Nathan P. Coussens Thomas Silvers Raymond G. Fox Samantha B. Kemp Poorva Juneja Joel Morris Melinda G. Hollingshead Naoko Takebe James H. Doroshow Beverly A. Teicher

View Full Paper

Ask AI

Bookmark

Share

Key Points

Combination therapy demonstrated significant activity against tumor spheroids with oncogenic kras variants, enhancing treatment efficacy.
Results highlight the effectiveness of batoprotafib combined with trametinib in multicell-type tumor spheroids.
This research involved the assessment of combination activity using patient-derived tumor models, emphasizing translational implications.
Findings suggest that this combination therapy may improve outcomes for patients with specific cancer types driven by kras mutations.

Implication

Combination therapy with ras pathway inhibitors shows activity in tumor spheroids, indicating potential treatment options.

Abstract

Figure S4. Combination activity of batoprotafib with trametinib in multicell-type tumor spheroids.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davoudi et al. (2025) studied this question.

synapsesocial.com/papers/68e861857ef2f04ca37e3b9f https://doi.org/10.1158/2767-9764.30304690

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S9 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
2Figure S11 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
3Figure S12 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
4Figure S15 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
5Figure S7 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025